Athira Pharma (ATHA) has priced its upsised IPO of 12M (from 10M) common shares at $17.00/share, for expected gross proceeds of $204M.
Athira is a biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration.
Trading commences September 18.
Underwriters’ over-allotment is an additional 1.8M shares.
Goldman Sachs, Jefferies, Stifel and JMP securities are acting as joint book-running managers.
Closing date is September 22.
The company’s lead candidate, ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule HGF/MET activator indicated for the treatment of Alzheimer’s disease.
https://seekingalpha.com/news/3615197-athira-pharma-prices-upsized-ipo-17
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.